Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Cash from Investing Activities (2020 - 2025)

Historic Cash from Investing Activities for Rani Therapeutics Holdings (RANI) over the last 6 years, with Q2 2025 value amounting to $5.7 million.

  • Rani Therapeutics Holdings' Cash from Investing Activities fell 1244.44% to $5.7 million in Q2 2025 from the same period last year, while for Sep 2025 it was $26.5 million, marking a year-over-year decrease of 1341.21%. This contributed to the annual value of $19.8 million for FY2024, which is 3366.04% down from last year.
  • According to the latest figures from Q2 2025, Rani Therapeutics Holdings' Cash from Investing Activities is $5.7 million, which was down 1244.44% from $18.2 million recorded in Q1 2025.
  • In the past 5 years, Rani Therapeutics Holdings' Cash from Investing Activities registered a high of $18.2 million during Q1 2025, and its lowest value of -$71.3 million during Q3 2022.
  • In the last 5 years, Rani Therapeutics Holdings' Cash from Investing Activities had a median value of $789000.0 in 2023 and averaged $39352.9.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first crashed by 17867.65% in 2022, then soared by 300459.52% in 2023.
  • Rani Therapeutics Holdings' Cash from Investing Activities (Quarter) stood at -$271000.0 in 2021, then crashed by 68.63% to -$457000.0 in 2022, then skyrocketed by 3004.6% to $13.3 million in 2023, then tumbled by 81.01% to $2.5 million in 2024, then skyrocketed by 126.62% to $5.7 million in 2025.
  • Its last three reported values are $5.7 million in Q2 2025, $18.2 million for Q1 2025, and $2.5 million during Q4 2024.